The disclosure is directed to compositions comprising an oncolytic virus, chimeric antigen receptor T cells (CAR T cells), a therapeutic or immunomodulating monoclonal antibody, a targeting thymidine kinase inhibitor (TKI), or an adoptively transferred cells incorporating engineered T cell receptors, and a live attenuated recombinant Listeria strain comprising a fusion protein of a Truncated LLO, a truncated ActA or a PEST-sequence peptide fused to a tumor-associated antigen. The disclosure is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering the same, with or without an additional radiation therapy treatment.本發明涉及組合物，其包括溶瘤病毒、嵌合抗原受體T細胞(CAR T細胞)、治療或免疫調節單株抗體、靶向胸苷激酶抑制劑(TKI)或併有經工程改造之T細胞受體之授受轉移細胞及活減毒重組李斯特菌菌株，所述李斯特菌菌株包括融合至腫瘤相關抗原之截斷LLO、截斷ActA或PEST序列肽之融合蛋白。本發明進一步涉及治療、防禦腫瘤及誘導針對腫瘤之免疫反應之方法，其包括在進行或不進行額外輻射療法治療之情況下投與所述組合物之步驟。
